Drugs / Insulin FiAsp
Insulin FiAsp
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT04460326 | Dec 2020 → May 2023 | type 2 diabetes mellitus | Boston Medical Center | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT03659799 Comparator | Apr 2019 → Dec 2022 | type 1 diabetes mellitus | Montreal Clinical Research Institute | Completed | No outcome recorded |
Press releases naming this drug 8 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Insulin FiAsp | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03659799 ↗ |
| Known as | faster acting Aspart | “faster acting Aspart (FiAsp) on glucose reduction during exercise.” NCT03659799 ↗ |
| Known as | FiAsp | “faster acting Aspart (FiAsp) on glucose reduction during exercise.” NCT03659799 ↗ |